Marie Ange is a Senior Engineer in Analytical Development Team, focusing on cell-based assays. She has over 26 years of experience in biotechnology sector, of which she spent over 18 years at Cellectis. 

Her work focuses on assay development, pre-qualification according to Regulatory Agencies guidelines and subsequent assay transfer to QC-lab (GMP-environment). 

The portfolio of her methodological experience includes among others: cell line engineering, T-Cell proliferation, Cytotoxicity and Cytokine secretion assays, flow cytometry, rLV production and titration.

Dr. Maria Caballero, biologist with a Ph.D. in Biomedicine and extensive expertise in drug discovery, specializing in the development of assays for diverse targets and phenotypes, applying a broad spectrum of cutting-edge technologies. Over the past two years, she has served as research officer in the drug-screening platform at the Institute for Research in Biomedicine (IRB) Barcelona. In this role, she has gained substantial experience running High Throughput Screenings (HTSs) campaigns, providing pivotal support for scientific projects, and conducting characterizations of compounds.

Gema Rojas obtained her bachelor's degree in Biomedicine from the University of Seville and completed her MSc in Bioinformatics at the Autonomous University of Barcelona.She worked as a data scientist at Leitat technological center for 1.5 years and then joined the Institute for Research in Biomedicine (IRB) in Barcelona to pursue her PhD in 2021. Her research focuses on developing new methods for drug repurposing and drug development by leveraging artificial intelligence and drug bioactivity descriptors.

In progress

Jérôme Cartry earned his PhD in Developmental Biology from Université Paris VI (Jussieu) in 2008, and furthered his research on genetic cardiac function at Sanford Burnham Prebys Medical Discovery Institute, San Diego. At Gustave Roussy Institute since 2015, he transitioned from a clinical research associate to a lab engineer in the Jaulin lab, focusing on translational research. Cartry's work employs organoid technology for developing personalized cancer therapies, aiming to closely align laboratory findings with clinical treatments to improve patient outcomes in oncology.

Jolanta Vidugiriene is a Group Leader in R&D at Promega leading development of new technologies for mechanistic studies of cell survival and adaptation, particularly those involved in regulation of cellular energy metabolism.  Prior to joining Promega, Jolanta was a Principal Investigator of a Howard Hughes International Grant, where she conducted collaborative research between the Department of Biochemistry, University of Wisconsin-Madison and Vilnius University, Lithuania. Jolanta received her Ph.D. in biochemistry from Vilnius University, completed post-doctoral studies at Boston Biomedical Research Institute and Laboratory of Molecular Parasitology, Rockefeller University.